Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Cortisol and Glucocorticoid Responses: Study Summary

Previous related pageVitamin D, Cortisol and Glucocorticoid Responses: Full StudyNext related pageVitamin D, Cortisol and Glucocorticoid Responses: Full Study
Study at a glance

How was vitamin D studied in cortisol, fatigue and steroid treatment?

This page summarises human trials and laboratory studies of vitamin D, cortisol and responses to steroid medicines. Cortisol is a hormone involved in the body’s stress response. The studies asked different questions about hormone patterns, fatigue and immune-cell activity. They did not show that vitamin D repairs the system that controls cortisol release.

Did vitamin D change cortisol levels in people?

A small trial in women with multiple sclerosis found no clear improvement in daily cortisol levels or their change across the day. A possible difference after waking was no longer clear after accounting for starting measurements. Fatigue and depressive symptoms did not clearly improve. A winter trial in men receiving inpatient care in a forensic setting also found no clear cortisol effect. Changes seen within one treatment group did not establish that vitamin D worked better than placebo.

Did vitamin D reduce fatigue in adults with low vitamin D?

Otherwise healthy adults with fatigue and low vitamin D received one supervised vitamin D3 dose or placebo. At four weeks, fatigue scores improved more with vitamin D on the main questionnaire. A second assessment did not show a clear difference. The trial did not measure cortisol or its control system. It therefore cannot explain the benefit through an effect on stress hormones or establish treatment for chronic fatigue syndrome or a long-term dosing plan.

Did vitamin D always improve immune-cell responses to steroid medicine?

Calcitriol, the active vitamin D hormone, changed how human immune cells grown in the laboratory responded to dexamethasone, a steroid medicine. The direction depended on the cell type and treatment sequence. These results cannot be combined into a claim that vitamin D always makes steroid treatment work better. They do not demonstrate a general hormone benefit, improved ability to cope with stress or restored control of cortisol in people.

Read the full article below ↓

The selected studies show vitamin D: glucocorticoid interactions in particular cell systems, but they do not establish that supplementation restores hypothalamic-pituitary-adrenal (HPA) axis feedback. Human cortisol trials were inconclusive or null, while a separate short fatigue trial found improvement on its primary symptom scale without measuring an HPA mechanism. For the detailed analysis, see Vitamin D, Cortisol and Glucocorticoid Responses: Full Study.

Cortisol trials did not demonstrate feedback restoration

In Rolf’s trial, women with relapsing-remitting multiple sclerosis received 4,000 IU vitamin D3 daily or placebo for approximately 16 weeks. The analysed population was small: 22 supplemented participants and 19 controls after exclusions. Vitamin D status increased, but daily cortisol and slope comparisons were null, with p=.915 and p=.347.

An awakening-response comparison gave p=.044 before adjustment and p=.066 after accounting for baseline response. Fatigue and depressive-symptom comparisons were also null. The study did not measure adrenocorticotropic hormone (ACTH) or conduct a dexamethasone feedback challenge. It therefore contributes to Vitamin D and the HPA Axis without demonstrating repair of the complete feedback system.

Hansen’s winter trial randomised 86 male forensic inpatients to 1,600 IU daily or placebo, with 78 completing. No significant cortisol effect was found. The principal treatment interactions for heart-rate variability and heart rate were also nonsignificant, p=.125 and p=.636. Significant recovery contrasts within one group do not establish a treatment difference between groups. These distinctions matter when interpreting Vitamin D and Stress Physiology and broader claims about resilience.

A fatigue benefit was specific to the trial and measurement

Nowak studied otherwise healthy fatigued adults aged 20 to 50 with vitamin D below 20 ng/mL. After a single supervised 100,000 IU dose or placebo, the four-week Fatigue Assessment Scale change was −3.3 versus −0.8 points, p=.01, in the 120-person per-protocol analysis.

A second fatigue-course assessment did not differ significantly: improvement was reported by 48% versus 37%, p=.22. The trial measured neither cortisol nor HPA feedback. Its short-term symptom finding does not establish the mechanism, treatment for chronic fatigue syndrome or a long-term dosing plan.

Cell responses differed with the experimental context

Xystrakis examined active calcitriol with dexamethasone in human T-cell cultures. The combination enhanced interleukin-10 (IL-10)-associated regulatory responses. Calcitriol prevented dexamethasone-associated receptor downregulation; it did not itself simply increase receptor expression. Seven unique resistant-asthma donors contributed to key comparisons, and a small oral active-calcitriol pilot assessed cellular responses rather than clinical asthma efficacy.

Kassi studied mixed peripheral immune cells from 12 vitamin-D-deficient women. Eleven-day calcitriol pretreatment attenuated selected dexamethasone-associated GILZ gene-expression and receptor-translocation responses, while concurrent exposure did not reproduce the same GILZ effect. The two studies differ in cell type, sequence and endpoint; their directions cannot be merged into one universal increase in glucocorticoid sensitivity.

These experiments illustrate Vitamin D Signalling Pathways, but neither measures central cortisol feedback. Their connection with Vitamin D and Hormones is a bounded interaction between signals, not a demonstrated clinical hormone benefit.

Conclusion

The evidence supports context-dependent cellular interactions and one bounded short-term fatigue result. It does not establish general cortisol normalisation, restored HPA feedback or improved psychological resilience. This VD3FL summary reports the selected studies without turning their research regimens into personal treatment advice.

Primary source and publication details

Hansen AL, Ambroziak G, Thornton D, Mundt JC, Kahn RE, Dahl L, Waage L, Kattenbraker D, Araujo P, Murison R, Rypdal K, Grung B. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):E3258. DOI 10.3390/nu12113258. PMID 33114392.

Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.

Nowak A, Boesch L, Andres E, Battegay E, Hornemann T, Schmid C, Bischoff-Ferrari HA, Suter PM, Krayenbuehl PA. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. Medicine. 2016;95(52):e5353. DOI 10.1097/md.0000000000005353. PMID 28033244.

Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.

Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. The Journal of clinical investigation. 2006;116(1):146-155. DOI 10.1172/jci21759. PMID 16341266.

Related reading

Physiology

Vitamin D and the HPA Axis

Explore how vitamin D interacts with the HPA axis and the body’s central stress-response system, including hormonal signalling, immune: endocrine coordination, circadian rhythm, and metabolic adaptation.

Read more →

Original sources

Source

Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial

This study investigated the effects of vitamin D supplements during winter on biological markers of stress resilience such as psychophysiological activity, serotonin, and cortisol in a placebo-controlled, randomized clinical trial.

Publication details

Hansen AL, Ambroziak G, Thornton D, Mundt JC, Kahn RE, Dahl L, Waage L, Kattenbraker D, Araujo P, Murison R, Rypdal K, Grung B. Vitamin D Supplementation during Winter: Effects on Stress Resilience in a Randomized Control Trial. Nutrients. 2020;12(11):E3258. DOI 10.3390/nu12113258. PMID 33114392.

Read more →
Source

Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells

Published in Cellular and molecular life sciences : CMLS (2016).

Publication details

Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou PE, Moutsatsou P, Papavassiliou AG. Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cellular and molecular life sciences : CMLS. 2016;73(22):4341-4354. DOI 10.1007/s00018-016-2281-3. PMID 27220430.

Read more →
Source

Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis

Multiple sclerosis (MS) has been associated with both a poor vitamin D status and hyperactivity of the hypothalamus: pituitary: adrenal (HPA) axis.

Publication details

Rolf L, Damoiseaux J, Huitinga I, Kimenai D, van den Ouweland J, Hupperts R, Smolders J. Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in neurology. 2018;9:263. DOI 10.3389/fneur.2018.00263. PMID 29755397.

Read more →
Source

Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients

Published in The Journal of clinical investigation (2006).

Publication details

Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O’Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. The Journal of clinical investigation. 2006;116(1):146-155. DOI 10.1172/jci21759. PMID 16341266.

Read more →